By subscribing to our newsletter, you agree to receive e-mail from us. The purpose of The ASCO Post Evening News (TAP-EN) is to keep you informed about the latest clinical news in the field of oncology. This is a weekday newsletter service, with occasional weekend service during important oncology meetings. We also suspend service of the Evening News between Christmas Eve and New Year’s Day.
All of the information contained within TAP-EN is related to the practice of clinical oncology, including but not limited to recently published research, scientific advancements, therapeutic developments, new drug approvals, professional development news, and announcements from cancer practices, institutions, and societies. Editions of TAP-EN may also contain links to full-text articles from The ASCO Post.
You are free to unsubscribe from TAP-EN at any time by following the unsubscribe instructions located at the bottom of each e-mail. Unsubscribes may take up to 10 days to go into effect.
We reserve the right to modify or discontinue TAP-EN at any time with or without notice to you and without assigning sufficient cause or reason for doing so. We will not be liable to you or any third party should we exercise this right.
We reserve the right to unsubscribe users of our newsletter service without notice. We will exercise this right with any subscriber whom we believe registered with false data.
Editions of TAP-EN may also contain advertising. These banner ads may link to external websites as directed by the advertiser.
Harborside Press publishes TAP-EN under a license arrangement with the American Society of Clinical Oncology. The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or the American Society of Clinical Oncology, Inc. (ASCO®). Follow this link to view the full Disclaimer statement.